Triple attack: virus therapy plus two drugs targets liver tumors
NCT ID NCT06283134
First seen Jan 10, 2026 · Last updated Jun 07, 2026 · Updated 27 times
Summary
This early-stage study tests a new treatment for people with colorectal cancer that has spread to the liver and hasn't responded to standard therapies. The treatment combines a modified virus (BioTTT001) that targets cancer cells, with two drugs (toripalimab and regorafenib) that boost the immune system and block tumor growth. The main goals are to check safety and find the best dose, with 60 adults aged 18-70 participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.